
software overlord @RapyutaRobotics, shitpost, dive and travel off the grid when possible
Bengaluru, India
Joined June 2009
- Tweets9.5K
- Following542
- Followers919
- Likes5.7K
Pinned Tweet
We at @RapyutaRobotics are hiring across a range of positions. Come help us define the future of cloud robotics #weAreHiring .
rapyuta-robotics.com/careers…
Dhananjay Sathe retweeted
Remember when Bloomberg literally ran the headline: "China's curing cancer faster and cheaper than anywhere else. But some worry they may be going too fast"?
Now look at how the Financial Times is framing this new FDA decision: "FDA rejects cancer drug invented in China in blow to Beijing's biotech sector."
A "blow to Beijing"? Chinese lung cancer patients ALREADY have this drug. Not only is it approved across China, it is covered by public health insurance, where a single vial costs roughly $100 USD (around $1,300 per treatment cycle before insurance even kicks in to cover most of the bill).
Meanwhile, in separate head-to-head trials, this exact Chinese drug beat Merck's Keytruda, which is Big Pharma's $30 billion-a-year cash cow and the best-selling cancer drug on earth. In the U.S., Keytruda carries a list price of over $12,500 per three-week dose, adding up to more than $200,000 a year.
So why did the FDA block this initial U.S. application? While a larger global trial is still wrapping up, the U.S. partner company applied first to use the drug for a smaller, harder-to-treat group of lung cancer patients whose previous treatments had failed. Even though the drug clearly slowed down tumor growth, the FDA rejected it, claiming that slowing tumors wasn't enough without stronger long-term survival proof and complaining that too many patients in the trial were Chinese.
Here is the kicker: a Harvard Medical School study found that over half (57%) of the cancer drugs fast-tracked onto the market by the FDA failed to prove within five years that they actually helped patients live longer or feel better. For years, the FDA happily let Western pharma giants charge Americans $200,000 a year for drugs that only slowed or shrank tumors on paper. Yet the moment a superior Chinese drug threatens Big Pharma's biggest monopoly and exposes what cancer treatment actually costs outside the U.S. pricing racket, the FDA suddenly discovers "strict standards."
Even if you take the FDA's red tape at face value, look at the media sickness on display. Western outlets are cheering a blocked lung cancer treatment like it is a geopolitical scoreboard win over China, when the only people being denied the option right now are Americans.
Imagine framing American cancer patients having fewer options while still paying $200,000 a year as "owning Beijing."
FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector ft.trib.al/RfC5vXI
Dhananjay Sathe retweeted
Everyone is all against alcohol and sugar now. But who was there when your life was falling apart?
It sure wasn’t fucking salad.
Dhananjay Sathe retweeted
just randomly remembered y'all were buying & selling JPEGs for thousands of dollars (and were, like, super serious about it) just 4 years ago
At this point normal typing experience and UX is the key differentiator for voice typing keyboards. The models are all
the same but there are many, many circumstances in which you can't use voice typing and you have to use the keyboard.
34
Dhananjay Sathe retweeted
This is a good filter for people who I don’t want to work with. Please understand how computers work. This isn’t even about understanding Docker. Any software person should know how the layers work at a high level and this is a VERYYYYY high level.
Dhananjay Sathe retweeted
Nvidia stock fell 12% because of election and another 10% because of erection
Dhananjay Sathe retweeted
the most import skill in 2026 is still being able to tell your agents "wtf is this crap, no, not like this"
if you stop doing that, you're basically fucked, despite what some devfluencers would like you to think.
Dhananjay Sathe retweeted
amazon workers pee in bottles to hit their quota on time
microsoft does another round of layoffs to cut opex and pump the stock
google does the same so the ceo can earn his stock based comp
chamath, the spac sellor, is now the voice of the American middle class
elon spends half a billion on elections, then wants to give every kid his stock. someone has to be the exit liquidity
but don’t worry.
any day now, every ceo will look up and say: friends, the stock has pumped enough. we have earned enough. let us share the ai dividend.
and we’ll all hold hands, and dance, and enjoy the fruits of agi.
Today we're launching Dollars 💰
Most AI startups spend so much time and effort building an AI product with negative gross margins. We skipped straight to the end.
We sell US dollar bills for $0.80.
TAM: $1T+ in circulation. We’re going after all of it.
Let’s scale to the moon together.
dollars for less dot com
💯
I see how some people can watch flashy robot demos on the timeline and think with a shiver that the robot apocalypse is around the corner, but reality check:
There is no robot in the world that can change the batteries in a jack-o-lantern.
If you have a robot friendly door handle it might be able to walk outside, pick it up, and carry it back inside. The robot could open the drawer with your batteries in it, but then things get tough.
Opening the package of AA batteries?
Extracting a precision screwdriver from its case?
Unscrewing four tiny screws that require a hard press and twist?
Popping batteries out of the case?
Yes, you could build and train a specialist robot to do that today, but there is a very long way to go to replace the full range of human capabilities. Near term doomer scenarios should stop at “secretly controlling humanity” instead of “wiping humanity out” 😀
64
Dhananjay Sathe retweeted
Person who is reverse engineering his tv gets banned from OpenAI
You aren't allowed to stop your tv from spying on your family. You have to ask for permission
Or, maybe, maybe we accelerate
































